Recombinant DNA (rDNA) refers to artificial DNA molecules that are created by combining genetic material from different sources. This technology involves the insertion of DNA fragments from one ...

Recombinant antibody technology has been leveraged to mitigate a range of common problems associated with hybridoma platforms, helping to facilitate the development of an entirely new class of ...

DUBLIN--(BUSINESS WIRE)--The "Protein Therapeutics - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global market for Protein Therapeutics was estimated at ...

The development of early monoclonal antibody (mAb) therapies centered around the hybridoma platform requires the production of target antigen or immunogen and animal immunizations. This means there ...